Risk Factors and Machine Learning Model for Beta-Lactam Drugs Related Acute Kidney Injury

Analysis of Risk Factors of Beta-Lactam Drugs Related Acute Kidney Injury in Hospitalized Patients and Developments of Machine Learning Model

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05533606

Enrollment

19000

Registered

2022-09-09

Start date

2022-07-01

Completion date

2023-06-30

Last updated

2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Beta-Lactam Antibiotic Toxicity (Diagnosis)

Keywords

Beta-Lactam drugs, Acute kidney injury, Pharmacoepidemiology, Miss diagnosis, Risk factors, Logic regression

Brief summary

Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. The clinical data of hospitalized patients received β-Lactam drugs from January 2018 to December 2020 was retrospectively analyzed. The multiple logistic regression analysis suggested that complicated with hypertension, anemia, pneumonia, shock, sepsis, heart failure, combined use of proton pump inhibitors (PPI), angiotensin-converting enzyme inhibitor (ACEI), angiotensin Ⅱ receptor antagonist (ARB) were independent risk factors for AKI related to β-Lactam drugs. In clinical practice, patients with acute kidney injury risk factors should be closely monitored for changes in their blood creatinine and urine output to avoid acute kidney injury. For patients who have suffered from acute kidney injury, the cause should be removed in time and corresponding symptomatic treatment should be given.

Interventions

DRUGBeta-Lactam Drugs

During hospitalization，patients used Beta-Lactam drugs.

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* All inpatients who used β-lactam drugs during hospitalization * Hospital stay ≥ 48h * Age ≥18 years * There are two or more blood creatinine tests during hospitalization

Exclusion criteria

* Hospital stay \< 48h * Age \<18 years * Glomerular filtration rate (GFR)\< 30ml/min/1.73m2 within 48 hours after admission * AKI was diagnosed on admission * Less than two Scr test results during hospitalization * The Scr values were always lower than 40 μmol/L during hospitalization * Cases with incomplete medical history information

Design outcomes

Primary

Measure	Time frame	Description
The incidence of acute kidney injury in hospitalized patients treated with β-lactam drugs	Through study completion，up to half a year.	To analyze the incidence of acute kidney injury in hospitalized patients after using β-lactam drugs and to build a prediction model.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026